Resonant Capital Advisors LLC Raises Stake in Cigna Group $CI

Resonant Capital Advisors LLC lifted its stake in Cigna Group (NYSE:CI) by 15.3% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,578 shares of the health services provider’s stock after purchasing an additional 209 shares during the quarter. Resonant Capital Advisors LLC’s holdings in Cigna Group were worth $522,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its stake in shares of Cigna Group by 10.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,056,806 shares of the health services provider’s stock worth $3,966,690,000 after acquiring an additional 1,094,327 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Cigna Group by 0.9% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 11,654,993 shares of the health services provider’s stock worth $3,834,493,000 after purchasing an additional 98,715 shares during the last quarter. Dodge & Cox raised its position in shares of Cigna Group by 1.3% in the 1st quarter. Dodge & Cox now owns 8,889,733 shares of the health services provider’s stock worth $2,924,722,000 after purchasing an additional 117,125 shares during the last quarter. GQG Partners LLC raised its position in shares of Cigna Group by 21.5% in the 1st quarter. GQG Partners LLC now owns 4,886,674 shares of the health services provider’s stock worth $1,607,716,000 after purchasing an additional 865,092 shares during the last quarter. Finally, Valeo Financial Advisors LLC raised its position in shares of Cigna Group by 86,071.1% in the 2nd quarter. Valeo Financial Advisors LLC now owns 3,475,282 shares of the health services provider’s stock worth $1,148,859,000 after purchasing an additional 3,471,249 shares during the last quarter. Institutional investors own 86.99% of the company’s stock.

Cigna Group Price Performance

Shares of CI opened at $301.84 on Monday. The firm has a market cap of $80.57 billion, a PE ratio of 16.48, a P/E/G ratio of 0.88 and a beta of 0.45. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 0.65. The firm has a fifty day simple moving average of $299.22 and a two-hundred day simple moving average of $307.54. Cigna Group has a 1-year low of $256.89 and a 1-year high of $350.00.

Cigna Group (NYSE:CI) last posted its quarterly earnings data on Thursday, July 31st. The health services provider reported $7.20 EPS for the quarter, beating analysts’ consensus estimates of $7.15 by $0.05. The company had revenue of $67.13 billion during the quarter, compared to analysts’ expectations of $62.61 billion. Cigna Group had a return on equity of 18.80% and a net margin of 1.92%.Cigna Group’s revenue for the quarter was up 11.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $6.72 earnings per share. Cigna Group has set its FY 2025 guidance at 29.600- EPS. On average, equities analysts anticipate that Cigna Group will post 29.77 EPS for the current year.

Cigna Group Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 18th. Stockholders of record on Thursday, December 4th will be given a dividend of $1.51 per share. The ex-dividend date of this dividend is Thursday, December 4th. This represents a $6.04 annualized dividend and a dividend yield of 2.0%. Cigna Group’s dividend payout ratio is presently 32.97%.

Analyst Ratings Changes

Several research analysts have issued reports on CI shares. Wells Fargo & Company lifted their target price on shares of Cigna Group from $340.00 to $354.00 and gave the stock an “equal weight” rating in a report on Tuesday, October 7th. Guggenheim restated a “buy” rating and issued a $350.00 price objective (down from $388.00) on shares of Cigna Group in a report on Monday, August 4th. Barclays boosted their price objective on shares of Cigna Group from $354.00 to $383.00 and gave the stock an “overweight” rating in a report on Thursday, September 4th. Weiss Ratings restated a “hold (c+)” rating on shares of Cigna Group in a research note on Friday. Finally, The Goldman Sachs Group assumed coverage on Cigna Group in a research note on Tuesday, October 14th. They issued a “buy” rating and a $370.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $369.89.

Insider Activity

In other news, insider Brian C. Evanko sold 5,368 shares of the company’s stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $300.00, for a total transaction of $1,610,400.00. Following the completion of the sale, the insider owned 51,182 shares of the company’s stock, valued at $15,354,600. This represents a 9.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Nicole S. Jones sold 28,526 shares of the company’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $300.00, for a total transaction of $8,557,800.00. Following the sale, the insider directly owned 25,648 shares of the company’s stock, valued at approximately $7,694,400. This represents a 52.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.70% of the stock is owned by corporate insiders.

About Cigna Group

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.